PROTECTIVE EFFICACY OF PERTACTIN CONTAINING ACELLULAR DPT VACCINES

M.V. Fesenko; L.S. Namazova

PROTECTIVE EFFICACY OF PERTACTIN CONTAINING ACELLULAR DPT VACCINES

M.V. Fesenko, L.S. Namazova

Abstract

Pertussis vaccination with the use of DPT vaccines is a necessary condition for fighting the infection called bordetella pertussis. At the same time, it is known that the use of whole cellular DPT vaccines is accompanied with high incidence of side effects and serious neurological complications, and, as a result, reasonable refuse from injections by the population. Creation of less reactogenic, acellular vaccines would not only permit to decrease the incidence of side effects, but also increase the efficiency of pertussis vaccination. Maximum protective effect is achieved by using threebcomponent vaccines ( 80%), containng pertactin — outer membrane protein b. pertussis. the absence of this antigen in twobcomponent DPT vaccines predetermines their significantly lower efficacy.
Key words: children, pertussis, acellular DPT vaccines, pertactin.

About the Authors

M.V. Fesenko

Scientific Center of Children's Health, Russian Academy of Medical Sciences, Moscow
Russian Federation

L.S. Namazova

Scientific Center of Children's Health, Russian Academy of Medical Sciences, Moscow
Russian Federation

References

1. Tan T., Trindade E., Skowronski D. Epidemiology of pertussis. Pediatr. Infect. Dis. J. 2005; 24 (5): 10–18.

2. О санитарно-эпидемиологической обстановке в Российской Федерации в 2006 году. Доступно на: www.rospotrebnadzor.ru/docs/doclad.

3. Справка о состоянии инфекционной заболеваемости в Российской Федерации за 6 месяцев 2007 года. Доступно на: www.rospotrebnadzor.ru/sanepid.

4. Diphtheria, tetanus and pertussis: recommendations for vaccine use and other preventive measures recommendations of the Immunization Practices Advisory Committee (ACIP). Morb. Mortal. Wkly. Rep. 1991; 40 (10): 1–28.

5. Edwards K., Decker M. Pertussis vaccine. Plotkin S.A., Orenstein W.A., eds. In: Vaccines. 4th edition. Philadelphia: Saunders. 2004. P. 471–528.

6. Mattoo S., Cherry J.D. Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies. Clin. Microbiol. Rev. 2005; 18: 326–382.

7. Cherry J.D., Olin P. The science and fiction of pertussis vaccines. Pediatrics. 1999; 104 (6): 1381–1383.

8. Hewlett E.L., Cherry J.D. New and improved vaccines against pertussis. Levine M.M., Woodrow G.C., Kaper J.B., Cobon G.S. eds. In: New Generation Vaccines 2nd ed. New York: Marcel Dekker. 1997. P. 387–416.

9. Cherry J.D. Pertussis. The trials and tribulations of old and new pertussis vaccines. Vaccine. 1992; 10: 1033–1038.

10. Edvards K., Decker M., Mortimer E. Vaccines. Eds. Plotkin S., Orenstein W. Saunders. 1999. P. 293–345.

11. Озерецковский Н.А., Чупринина Р.П. Вакцинопрофилактика коклюша - итоги и перспективы. Вакцинация. 2004; 5 (35): 2–3.

12. Swedish Institute for Infectious Disease Control. Pertussis surveillance in Sweden. October 1997. September 2005. July 2006.

13. URL: www.smittskyddsinstitute.se/upload/Publicationer/SMI-rapport-2006-4.pdf.

14. Leninger E., Roberts M., Kenimer J.G. et al. Pertactin, an Arg-Gly-Asp-containing Bordetella pertussis surface protein that promotes adherence of mammalian cells. Proc. Natl. Acad. Sci. USA. 1991; 88 (2): 345–349.

15. Shahin R., Brennan Z., Meade B. et al. Characterization of the protective capacity and immunogenicity of the 69 kD outer membrane protein of Bordetella pertussis. J. Exp. Medicine. 1990; 171: 63–73.

16. Cherry J., Gornbein J., Heininger U. et al. A search for serologic correlates of immunity to Bordetella pertussis cough illnesses. Vaccine. 1998; 16 (20): 1901–1906.

17. Storsaeter J., Hallander H.O., Gustafsson L., Olin P. Low levels of antipertussis antibodies plus lack of history of pertussis correlate with susceptibility after household exposure to Bordetella pertussis. Vaccine. 2003; 21 (25-26): 3542–3549.

18. Jefferson T., Rudin M., DiPietrantonj C. Systematic review of the effect of pertussis vaccines in children. Vaccine. 2003; 21 (17-18): 2003–2014.

19. Gustafsson L., Hallander H.O., Olin P. et al. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N. Engl. J. Med. 1996; 334 (6): 349–355.

20. Greco D., Salmaso S., Mastrantonio P. et al. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. N. Engl. J. Med. 1996; 334 (6): 341–348.

21. Poolman J.T., Hallander H.O. Acellular pertussis vaccines and the role of pertactin and fimbriae. Expert. Rev. Vaccines. 2007; 6 (1): 47–56.

22. Cherry J.P. Comparative efficacy of acellular pertussis vaccines: an analysis of recent trials. Pediatr. Infect. Dis. J. 1997; 16 (4): 90–96.

23. Edwards K.M., Decker M.D. Acellular pertussis vaccines for infants. NEJM. 1996; 334 (6): 391–392.

24. Use of diphtheria toxoid-tetanus toxoid-acellular pertussis vaccine as a five dose series. Supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb. Mortal. Wkly. Rep. 2000; 49: 1–8.

Review

For citations:

Fesenko M., Namazova L. PROTECTIVE EFFICACY OF PERTACTIN CONTAINING ACELLULAR DPT VACCINES. Current Pediatrics. 2008;7(2):77-81.

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International.

ISSN 1682-5527 (Print)
ISSN 1682-5535 (Online)

Username
Password
	Remember me
Not a user? Register with this site Forgot your password?

User

Current Pediatrics

PROTECTIVE EFFICACY OF PERTACTIN CONTAINING ACELLULAR DPT VACCINES

Abstract

About the Authors

References

Review

For citations:

Cookies policy